Peripheral blood studies revealed epigenetic factors that can be used as prognostic markers as well as possible therapeutic targets, such as TRPA1, which has been intensively investigated as a pharmaceutical target for persistent nociceptive pain [59,60], and PARK2, previously known for its heritability in Parkinson’s disease [61]. This evidence concerns the gene PRKN and Parkinson disease.